REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock?

Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market.The company recently entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio.The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a...